DEEPECHO

DeepEcho Receives FDA 510(k) Clearance for AI-Powered Fetal Ultrasound Analysis Platform

- The US Food and Drug Administration has granted 510(k) clearance to DeepEcho's AI-powered fetal ultrasound analysis platform, marking a significant milestone in prenatal care technology. - The platform utilizes advanced deep learning algorithms trained on one of the world's largest fetal ultrasound datasets to automate real-time detection of fetal ultrasound views and improve diagnostic accuracy. - DeepEcho is developing next-generation solutions to identify novel biomarkers for early prediction of complex conditions like preeclampsia, a leading cause of maternal and neonatal mortality. - The company aims to democratize access to quality fetal ultrasound diagnostics globally, addressing critical challenges from diagnostic variability in developed markets to skilled radiologist shortages in emerging regions.